Thermaquil is developing a reversible nerve block device that utilizes targeted nerve modulation to manage severe pain without the use of pharmaceuticals or electrical stimulation. This technology addresses the need for effective pain management solutions that minimize reliance on drugs and reduce potential side effects associated with traditional pain relief methods.
Funding
$410K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current pain management strategies often rely on pharmaceuticals or electrical stimulation, which can lead to undesirable side effects or limited efficacy for severe pain. There is a need for non-pharmacological pain relief solutions that can provide targeted and reversible nerve modulation.
Solution
Thermaquil is developing a device that utilizes targeted nerve modulation to provide reversible nerve blocks for managing severe pain. The device aims to offer an alternative to traditional pain management methods by avoiding pharmaceuticals and electrical stimulation. By selectively modulating nerve activity, the technology seeks to provide effective pain relief while minimizing the risk of side effects associated with drug-based interventions. The company is also open to developing custom devices to block pain and treat other conditions caused by overactive nerves.
Target Audience
The primary target audience includes patients suffering from severe pain, healthcare providers seeking alternative pain management solutions, and potential partners and investors interested in innovative medical devices.
Features
- Targeted nerve modulation for precise pain management
- Reversible nerve block technology
- Non-pharmaceutical approach to pain relief
- Avoidance of electrical stimulation
- Potential for custom device development for various nerve-related conditions